Quick Answer
Bionano Genomics, Inc. reported Research And Development Expense of $11.37 million for the year ending 2025.
- Bionano Genomics, Inc. showed a decrease of -54.1% in Research And Development Expense from 2024 to 2025.
- This data is from Bionano Genomics, Inc.'s annual report (Form 10-K), filed with the SEC on March 23, 2026.
- XBRL data for this metric is available from 2017 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2017: $2.97 million | Q1 2018: $2.37 million | Q2 2018: $2.10 million | Q3 2018: $2.51 million | Q1 2019: $2.10 million | Q2 2019: $2.41 million | Q3 2019: $2.17 million | Q1 2020: $2.67 million | Q2 2020: $2.40 million | Q3 2020: $2.30 million | Q1 2021: $2.68 million | Q2 2021: $4.09 million | Q3 2021: $6.51 million | Q1 2022: $10.53 million | Q2 2022: $11.77 million | Q3 2022: $12.74 million | Q1 2023: $13.94 million | Q2 2023: $14.61 million | Q3 2023: $13.79 million | Q1 2024: $9.78 million | Q2 2024: $6.83 million | Q3 2024: $4.72 million | Q1 2025: $2.37 million | Q2 2025: $2.93 million | Q3 2025: $2.84 million.
- Over the full 9 years of available data (2017 to 2025), Bionano Genomics, Inc.'s Research And Development Expense has declined by 5.3%.
- Historical annual values: Fiscal year 2025: $11.37 million | Fiscal year 2024: $24.80 million | Fiscal year 2023: $54.03 million | Fiscal year 2022: $49.05 million | Fiscal year 2021: $22.49 million | Fiscal year 2020: $10.26 million | Fiscal year 2019: $9.08 million | Fiscal year 2018: $9.48 million | Fiscal year 2017: $12.01 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: